Annual trends in GVHD prophylaxis using ATG in BMT and PBSCT in Japan

Souichi Shiratori; Marie Ohbiki; Noriko Doki; Takahiro Fukuda; Satoshi Yoshihara; Yoshinobu Kanda; Tetsuya Nishida; Noboru Asada; Hirohisa Nakamae; Yuta Hasegawa; Yoshiko Atsuta; Takanori Teshima

doi:10.7889/tct-24-022

Brief Communication

Annual trends in GVHD prophylaxis using ATG in BMT and PBSCT in Japan

Souichi Shiratori, Marie Ohbiki, Noriko Doki, Takahiro Fukuda, Satoshi Yoshihara, Yoshinobu Kanda, Tetsuya Nishida, Noboru Asada, Hirohisa Nakamae, Yuta Hasegawa, Yoshiko Atsuta, Takanori Teshima

Author information

Souichi Shiratori
Department of Hematology, Hokkaido University Hospital
Marie Ohbiki
Japanese Data Center for Hematopoietic Cell Transplantation
Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine
Noriko Doki
Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
Takahiro Fukuda
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital
Satoshi Yoshihara
Department of Hematology, Hyogo Medical University Hospital
Yoshinobu Kanda
Division of Hematology, Jichi Medical University Saitama Medical Center
Tetsuya Nishida
Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital
Noboru Asada
Department of Hematology and Oncology, Okayama University Hospital
Hirohisa Nakamae
Department of Hematology, Osaka Metropolitan University Hospital
Yuta Hasegawa
Department of Hematology, Hokkaido University Hospital
Yoshiko Atsuta
Japanese Data Center for Hematopoietic Cell Transplantation
Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine
Takanori Teshima
Department of Hematology, Hokkaido University Hospital
Department of Hematology, Hokkaido University Faculty of Medicine

Keywords: allogeneic hematopoietic stem cell transplantation, bone marrow transplantation (BMT), peripheral blood stem cell transplantation (PBSCT), antithymocyte globulin (ATG), posttransplant cyclophosphamide (PTCy)

JOURNAL FREE ACCESS

2025 Volume 14 Issue 2 Pages 110-113

DOI https://doi.org/10.7889/tct-24-022

Details

Abstract

Graft-versus-host disease (GVHD) prophylaxis using antithymocyte globulin (ATG) has been well-established in allogeneic hematopoietic stem cell transplantation. We collected data on GVHD prophylaxis from 27,091 cases of hematological malignancies undergoing bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) from 2010 to 2022. Annual trends in GVHD prophylaxis were analyzed based on donor type, stem cell source or HLA compatibility. The number of GVHD prophylaxis using ATG was increased in related-HLA matched-PBSCT [2010: n＝6 (1.6%), 2022: n＝42 (14.1%)], unrelated-HLA matched-PBSCT [2010: n＝0 (0.0%), 2022: n＝80 (43.0%)], unrelated-HLA 1-locus mismatched-BMT [2010: n＝36 (9.6%), 2022: n＝97 (40.4%)], and unrelated-HLA 1-locus mismatched-PBSCT [2010: n＝0 (0.0%), 2022: n＝64 (59.3%)]. Conversely, ATG use decreased in related-HLA haplo-PBSCT [2010: n＝111 (67.7%), 2022: n＝63 (11.2%)] due to the increasing use of posttransplant cyclophosphamide (PTCy). This study highlights the variation in GVHD prophylaxis trends using ATG across transplantation types.

Corresponding author

Register with J-STAGE for free!